A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Enovis Corporation ENOV

Mixed (graded 2026-09-05, not re-checked) broader-coverage candidate · Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices.

On FrontierLab's discovery record since 2026-07-27 (10 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-05), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	4.9%
Gross margin	57.4%
Gross profits / assets	0.35
Rule of 40	9
Net margin	4.1%
Cash runway (months)	—
PEG	—
Price / sales	0.5

Quality checklist

✗ Revenue growth — 4.9% (pass ≥ 20%)
✓ Gross profits / assets — 0.35 (pass ≥ 0.33)
~ Gross margin — 57.4% (pass ≥ 60%)
✓ Cash generation
~ Share dilution — 1.4%

Fundamentals — snapshot as of 2026-09-05

Stage	Established
Share issuance (YoY)	1.4% · modest issuance
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-19.40
Burn multiple	—
Gross-margin trend (pts)	-0.2
Cash / assets	0
Net debt / EBITDA	—
Statements as of	Q2 FY2026 · filed 2026-08-06

Momentum context — a snapshot from 2026-09-05, not current

Price at surface	$18.56 (as of 2026-09-05)
52-week range	$18.52 – $34.28
% off 52-wk high	-45.9%
RSI (14)	26
Relative volume	1.6×

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-09-05 (end-of-day). How grades are computed →